Abstract
Blood-spinal cord barrier (BSCB) plays an important role in the regulation of the fluid microenvironment of the spinal cord. Trauma to the spinal cord impairs the BSCB permeability to proteins leading to vasogenic edema formation. Several endogenous neurochemical mediators and growth factors contribute to trauma induced BSCB disruption. Studies carried out in our laboratory suggest that those drugs and neurotrophic factors capable to attenuate the BSCB dysfunction following trauma are neuroprotective in nature. Whereas, agents that do not exert any influence on the BSCB disruption failed to reduce cell injury. These observations are in line with the idea that BSCB disruption plays an important role in the pathophysiology of spinal cord injuries. The probable mechanism(s) of trauma induced BSCB dysfunction and its contribution to cell injuries are discussed.
Keywords: blood-spinal cord barrier, spinal cord edema, spinal cord evoked potentials, cell injury, glial fibrillary acidic protein, myelin basic protein, neurotrophic factors, regeneration, nitric oxide, carbon monoxide
Current Pharmaceutical Design
Title: Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Volume: 11 Issue: 11
Author(s): Hari Shanker Sharma
Affiliation:
Keywords: blood-spinal cord barrier, spinal cord edema, spinal cord evoked potentials, cell injury, glial fibrillary acidic protein, myelin basic protein, neurotrophic factors, regeneration, nitric oxide, carbon monoxide
Abstract: Blood-spinal cord barrier (BSCB) plays an important role in the regulation of the fluid microenvironment of the spinal cord. Trauma to the spinal cord impairs the BSCB permeability to proteins leading to vasogenic edema formation. Several endogenous neurochemical mediators and growth factors contribute to trauma induced BSCB disruption. Studies carried out in our laboratory suggest that those drugs and neurotrophic factors capable to attenuate the BSCB dysfunction following trauma are neuroprotective in nature. Whereas, agents that do not exert any influence on the BSCB disruption failed to reduce cell injury. These observations are in line with the idea that BSCB disruption plays an important role in the pathophysiology of spinal cord injuries. The probable mechanism(s) of trauma induced BSCB dysfunction and its contribution to cell injuries are discussed.
Export Options
About this article
Cite this article as:
Sharma Shanker Hari, Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair, Current Pharmaceutical Design 2005; 11 (11) . https://dx.doi.org/10.2174/1381612053507837
DOI https://dx.doi.org/10.2174/1381612053507837 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Therapeutic Potential of Adult Neural Stem Cells
Recent Patents on CNS Drug Discovery (Discontinued) Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Possible Neuroprotective Strategies in ALS
Current Neuropharmacology Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Regenerative Medicine for Spinal Cord Injury
Recent Patents on Regenerative Medicine Ion Selective Electrodes for Potentiometric Determination of Tizanidine in Its Pharmaceutical Dosage Form
Current Pharmaceutical Analysis The Role of CD8+ T Cells in Multiple Sclerosis and its Animal Models
Current Drug Targets - Inflammation & Allergy Modelling and Treating Amyotrophic Lateral Sclerosis through Induced- Pluripotent Stem Cells Technology
Current Stem Cell Research & Therapy Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases
Current Medicinal Chemistry Pituitary Adenylate Cyclase Activating Polypeptide in Animal Models of Neurodegenerative Disorders - Implications for Huntington and Parkinsons Diseases
Letters in Drug Design & Discovery The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research